Detalhe da pesquisa
1.
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
Qual Life Res
; 32(1): 183-196, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36029412
2.
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
Am J Hematol
; 93(4): 486-493, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29266344
3.
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
J Cancer Res Clin Oncol
; 149(15): 14125-14136, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552307
4.
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
J Clin Oncol
; 41(2): 186-197, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166727